Maria Guerrero

Internal Medicine
Endocrinology- Diabetes Tech

[Maria Guerrero @MariaGuerreroD]

Con #vivera aproximadamente 50% de los pacientes alcanza metas de tiempo en rango estrecho (TTR) @minimed #ATTD2026

[Maria Guerrero @MariaGuerreroD]

Nuevo algoritmo #vivera de @minimed
#ATTD2026

[Maria Guerrero @MariaGuerreroD]

El futuro de la diabetes: la IA será el puente entre la tecnología y la biología #ATTD2026

[Maria Guerrero @MariaGuerreroD]

Aunque ampliamente utilizado para valorar el rendimiento del monitoreo continuo de glucosa, por sí solo el MARD es una medida imperfecta #ATTD2026

[Maria Guerrero @MariaGuerreroD]

Barcelona 🤩 #attd2026

[Maria Guerrero @MariaGuerreroD]

Hablando de disruptores endocrinos y enfermedades tiroideas entre colegas y amigos en el #Thyroidsummit en Medellín, Colombia

[NEJM @NEJM]

Presented at #ECO2025:

In the SURMOUNT-5 phase 3b trial involving adults with obesity without type 2 diabetes, tirzepatide was superior to semaglutide in reducing body weight and waist circumference. Full trial results: https://t.co/mDYfCO3Bqy

@EASLnews

[@carogomezmartin @carogomezmartin]

Objetivos personalizados y necesidad de “realinear” los tratamientos en adultos mayores…
#ATTD2025
@ATTDconf

[@carogomezmartin @carogomezmartin]

⚠️ Los momentos “aha”‼️

👉🏻Todas estas situaciones que alteran los niveles de glucosa…

🎯El #MCG identificarlas y modificar los hábitos!

#ATTD2025
@ATTDconf

[Kamil @nerdabetic]

Kaleido patch pump is back. They re-entered the diabetes tech space big time with a great event at #ATTD2025 today. They scalling up manufacturing and many users are already using it with @Diabeloop hybrid closed loop. They also revealed Kaleido 2- launching next year.

[Maria Guerrero @MariaGuerreroD]

Nuevos sistemas, nuevos algoritmos #ATTD2025

[Tadej Battelino @TBattelino]

Hyperglycemia (HIGH glucose) seem to be the culprit for autonomic neuropathy:
👉🏿surprise for the hypo focused 😉
👉🏿actionable & preventable 🤘🏽👍🏿
@AjjanRamzi #ATTD2025 @parthaskar @WilmotEmma @drpratikc @ATTDconf @AbbottNews

[Ascensia Diabetes Care @AscensiaGlobal]

BREAKING NEWS

We are thrilled to announce that we have received clearance from the US Food and Drug Administration (FDA) for Eversense® 365 CGM system, The World’s First One Year CGM.

With a single sensor, the Eversense 365 system provides one year of use, versus 10-14 days with short-term CGM’s for minimal life disruption. Eversense 365 is supporting people with diabetes to live life uninterrupted, as a fully-implantable, long-term CGM option that is highly-differentiated from short-term CGMs.

Check out the press release for more details: https://t.co/0QW40ywndo

To learn more about Eversense and for additional information about when Eversense 365 will be available, go to https://t.co/oJSd6MEjMz

#Eversense365 #Diabetes #DiabetesCare #DiabetesManagement #MedTech

[Dr Alo, DO, FACC @MohammedAlo]

Eat Your Rainbows 🌈: Fruits & Vegetables

Despite the clear health benefits of consuming fruits and vegetables, 78% of adults worldwide do not eat the daily recommended servings.

8 out of 10 American adults fall short in every colour of phytonutrient.

A total of 86 studies were included, covering 449 health outcomes analysed together, with data from over 37 million participants.

The review found that consuming 3 or more types of bioactive pigments improved many health outcomes:

1️⃣ Risk of all-cause mortality
2️⃣ Risk of cardiovascular disease, coronary heart disease, stroke, ischemic heart disease
3️⃣ Risk of 17 types of cancers
4️⃣ Glycemic & insulinemic biomarkers, Lipid profiles (HDL cholesterol, total cholesterol)
5️⃣ Body weight, BMI, waist circumference
6️⃣ Vascular function, blood & arterial pressure
7️⃣ Inflammatory & oxidative stress biomarkers
8️⃣ Type 2 diabetes mellitus and Hypertension risk
9️⃣ Risk of hip fracture, total fracture
1️⃣0️⃣ Cognitive function

Conclusion: Eating a diverse range of fruits and vegetables was associated with significant health benefits

Limitation: Most of the outcomes showed low confidence in the results, with 91% having a rating of very low or low certainty.

Like, Retweet and Bookmark🔖

Review Link: https://t.co/aNdcn5n1yO

[Kidney International @Kidney_Int]

Deciphering the kidney hemodynamic effects of #SGLT2 inhibition: translating insights from rats to humans in type 2 diabetes

https://t.co/bYbGv22V4z

Original article:
https://t.co/Fuk5dIXyGq

@UWDeptMedicine @medcmuofficial
#KICommentary #diabetes

[Diana Isaacs, PharmD, BC-ADM, CDCES @DianaMIsaacs]

Omnipod5 is FDA approved for #T2D! First FDA approved AID system for people with type 2! Same system as that uses in #T1D. An extra 30 minute pre-training will be required. https://t.co/SxHXsCLGd4

[MiniMed @minimed]

Announcing a new partnership with Abbott!

Our companies are collaborating on a sensor based on Abbott’s most advanced CGM platform that will work exclusively with Medtronic technology. We'll share more updates as the partnership progresses.

We're excited to offer more options to our customers!

[Scott Isaacs @scottisaacsmd]

There is no convincing data to support the use of CGMs in people without diabetes. There are no clear glucose metrics or clinical benchmarks for this population as well as the lack of compelling evidence for the utility of CGM in this context.
https://t.co/p3M0TLanMQ

[David G. Armstrong follow @dgarmstrong.bsky.social @DGArmstrong]

How to do a 3 Minute Diabetic Foot Exam and #ActAgainstAmputation

[Pablo Corral MD @drpablocorral]

👏Great Session at @AmDiabetesAssn by @ErinMichos regarding New Lipid-Lowering Pharmacotherapies in Diabetes

#ADASciSessions